Bessemer Group’s 10x Genomics TXG Stock Holding History

Bessemer Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-174	Closed	-$26.7K	–	1977
2021 Q3	$25K	Buy	+174	New	+$29.9K	﹤0.01%	1191

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bessemer Group's TXG Position: Q4 2021 in Review

Bessemer Group sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 174 shares — an estimated $26.7K sold.

Bessemer Group first reported a position in TXG in Q3 2021 and held it in 1 quarter. The position peaked at $25K in Q3 2021. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

Bessemer Group reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
Bessemer Group sold 174 10x Genomics shares in Q4 2021, an estimated $26.7K.
Bessemer Group first reported a position in 10x Genomics in Q3 2021 and held it in 1 quarter.
Bessemer Group's 10x Genomics position peaked at $25K in Q3 2021.
365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Bessemer Group's 13F filing for Q4 2021, filed 27 Jan 2022.